COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

Launched by ODENSE UNIVERSITY HOSPITAL · Feb 16, 2022

Keywords

ClinConnect Summary

The COLA trial is studying how to improve treatment for patients with locally advanced non-small cell lung cancer (NSCLC) who are receiving chemotherapy and radiation therapy. The goal is to understand how this treatment affects the heart, as well as how well it works for the cancer. Participants will have regular heart check-ups, including an electrocardiogram (ECG) and a cardiac MRI, for at least two years after their treatment to monitor for any heart issues.

To be eligible for this trial, participants need to be at least 18 years old, have a confirmed diagnosis of inoperable NSCLC, and plan to undergo treatment aimed at curing the cancer. They must also be able to complete the required heart tests and provide written consent to take part in the study. It’s important to note that people with certain heart devices, severe anxiety in confined spaces (claustrophobia), or other specific medical conditions may not be able to join the trial. This study is currently recruiting participants of all genders, aged 65 to 74 or older, to help advance our understanding of cancer treatment and its impact on heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 Years
• • Inoperable and histologically/cytologically verified NSCLC.
• • Planned treatment with curative intent.
• • Capable of completing study procedures ECG and Cardiac MR.
• • Able of giving written and informed consent before study procedures are initiated.
• Exclusion Criteria:
• • Vulnerable patients.
• • Patients with operable devices as pacemaker/ICD and cochlear implant or other conditions where MR scan is contraindicated.
• • Claustrophobia.